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SUMMARY 
Tuberculosis (TB) is an infectious disease associated with significant mortality and morbidity worldwide, 
particularly in developing countries. The rise of antibiotic resistance in Mycobacterium tuberculosis (Mtb) 
urgently demands the development of new drug leads to tackle resistant strains. Fragment-based 
methods have recently emerged at the forefront of pharmaceutical development as a means to generate 
more effective lead structures, via the identification of fragment molecules that form weak but high 
quality interactions with the target biomolecule and subsequent fragment optimization. This review 
highlights a number of novel inhibitors of Mtb targets that have been developed through fragment-based 
approaches in recent years. 
 
INTRODUCTION 
Tuberculosis 
Tuberculosis (TB) is a disease caused by the pathogen Mycobacteium tuberculosis (Mtb). According to 
the World Health Organisation (WHO) in 2014 it was estimated that 1.5 million people died as a result of 
the disease and a further 9.6 million people were infected (WHO Report, 2015). This has been further 
complicated by the fact that there has been a rise in the multidrug resistant (MDR), extensively drug 
resistant (XDR) and totally drug resistant (TDR) forms of Mtb.  
 The current drug regimen for the treatment of TB involves a lengthy treatment program of over 
6 months and in some cases this can last 1-2 years in the case of MDR and XDR-TB strains. The drugs 
used to treat TB have not changed much since the 1960’s and there are significant toxic side effects 
associated with the long-term usage of these drugs. In recent years there has been resurgence in 
interest in TB as a target for drug discovery. The increase in the number of people infected with 
resistant strains of Mtb [e.g. MDR-TB] offers the biggest challenge in tackling this disease and because 
of this there is the urgent need to develop new drugs against novel targets in Mtb. The development and 
the subsequent FDA approval of the drug Bedaquiline which targets ATP synthase was a significant 
step in this respect.(Koul et al, 2011) This was the first drug to be approved in over 40 years for the 
treatment of TB.   
 
Fragment-based drug discovery 
 Fragment-based approaches to drug-discovery are now firmly established in both academia 
and industry. Fragment-based drug discovery (FBDD) is now routinely run alongside high-throughput 
screening (HTS) campaigns and there has been notable successes with certain targets where HTS 
campaigns have failed.(Scott et al, 2012)(Congreve et al, 2008) In 2016 the second drug developed 
using this methodology was approved by the FDA following on from Vemurafenib which was approved 
in 2011.  
 The fragment-based approach involves the screening of a fragment library (1000-5000 
fragments) against a target using a range of biophysical techniques. The fragments (typically molecular 
weight < 250 Da) bind with affinities of 0.1 - 5.0 mM, and the biophysical techniques need to have the 
sensitivity required to detect these interactions. A wide range of biophysical techniques have been 
explored for fragment screening including differential scanning fluorimetry (DSF), surface plasmon 
resonance (SPR), ligand and protein based NMR.(Mashalidis et al, 2013) However the one technique 
which has proven crucial for this approach has been X-ray crystallography.(Murray et al, 2010) This 
provides a key insight into how fragments bind to the target protein. Once the fragments have been fully 
characterized the next step is to increase their affinity. The fragment elaboration strategies that are 
employed include fragment growing, fragment merging and fragment linking. Fragment growing is the 
strategy used the most frequently and this involves ‘growing’ a fragment using synthetic organic and 
medicinal chemistry. Structural information from X-ray crystal structures is a key aspect for fragment 
growing.   
Fig 1: Fragment elaboration strategies 
 
Fragment merging is the incorporation of the structural aspects of overlapping fragments, substrates 
and other ligands. Fragment linking involves the linking of two or more fragments at non-overlapping 
binding sites. The linking of two fragments is one of the most appealing strategies as the binding affinity 
of the linked compounds is expected to have a Gibbs free energy greater than the sum of the individual 
fragment binding energies (superadditivity effect). However, in practice this strategy is one of the most 
difficult to achieve. These elaboration strategies will be discussed in this review in the context of 
fragment-based approaches for the development of novel Mtb inhibitors. 
 
ENZYME TARGETS FOR TB DRUGS 
 (a) Coenzyme A biosynthetic pathway 
 The Coenzyme A (CoA) biosynthetic pathway enzymes are validated targets for the treatment 
of Mtb infections. CoA is one of the most widely used of all the enzyme cofactors; it is required by both 
prokaryotic and eukaryotic cells for fatty acid biosynthesis and breakdown and for respiration, due to its 
role in the Krebs cycle. The terminal thiol functionality of CoA forms thioesters with carboxylic acids of 
different lengths (from two carbons group to entire fatty acids) and this specific reactivity allows CoA to 
act an acyl group carrier, which is the main role of this cofactor. 
 The protein members of the CoA biosynthetic pathway have been extensively characterized. 
The cofactor is the product of two different pathways, the first of which is responsible for the production 
of panthotenic acid (or Vitamin B5) that is then used as substrate via five enzymatic steps to obtain the 
final CoA. Because of CoA essentiality, the enzymes involved in the pathway have been proposed as 
novel targets for the development of drugs for the treatment of Mtb infections, with the aim of 
overcoming the intrinsic resistance to current treatments. In particular the panthotenic acid pathway 
fulfils all the requisites required by a broad spectrum antibacterial target: it is essential for the 
mycobacterium survival and is exclusive for bacteria, since eukaryotic cells are not able to produce 
Vitamin B5 and have to assume it from the extracellular environment (Spry et al. 2008). 
 The panthotenic acid biosynthetic pathway consists of three enzymatic reactions, α-
ketoisovalerate is first transformed into ketopantoic acid by ketopantoate hydroxymethyltransferase 
(KPHMT product of the panB gene), which is then reduced by ketopantoate reductase (KPR or panE) to 
pantoic acid. Finally pantoic acid is condensed with β-alanine (deriving from aspartic acid (Asp) thanks 
to the activity of aspartate decarboxlase, ADC) by panthotenate synthetase (PS or panC) to give 
pantothenic acid (Webb et al. 2002). 
 The role of PS as an Mtb target has been validated in genetic studies by proving that an 
auxotrophic mutant of Mtb defective in panC showed reduced virulence in both immunocompromised 
and immunocompetent mice (Sambandamurthy et al. 2002). Furthermore the presence of several X-ray 
crystal structures for the enzyme, in its dimeric apo form as well as in complex with its substrates or the 
pantoyladenylate intermediate, facilitates the structure-based inhibitor design following the fragment hit 
identification. This makes PS a very promising target from a FBDD perspective (Wang et al. 2003). 
 Ciulli and co-workers explored PS as target using an integrated biophysical approach (thermal 
shift, NMR, ITC, X-ray crystallography) for fragment screening and validation (Silvestre et al. 2013). A 
‘rule of three’ compliant fragment library of 1,250 compounds was screened using thermal shift, with a 
fixed threshold value (0.5 °C at 10 mM)(Fig. 2). Thirty-nine fragments were identified (3.1% hit rate) and 
seventeen hits were confirmed to bind using ligand-based NMR techniques (WaterLOGSY and STD). 
This approach based on the use of several biophysical techniques proves that the success rate 
obtained by an initial thermal shift screening followed by NMR is higher compared to a NMR-based 
fragment screen: the same group performed a simplified NMR screen against PS using 52 fragments 
with the identification of only one ATP-competitive inhibitor, 5-methoxyindole 2 (Hung et al. 2009). The 
fragments were further characterised using isothermal titration calorimetry (ITC) where KD values were 
measured and were found to be in the range of 0.5 to 1.7 mM. Subsequent examination of the binding 
of the fragments to PS with X-ray crystallography allowed the identification of three different binding 
pockets in the PS active site: the recognition site of the ATP adenine motif, the pantoate binding site 
(P1) and the pyrophosphate and β-alanine binding pocket (P2).  
 This initial work was followed by the fragment elaboration strategies using structure-based 
approaches. 5-Methoxyindole 2, KD of 1.1 mM (LE = 0.36), was found to bind at the recognition site of 
the ATP adenine motif in the crystal structure and was selected as a startpoint for a fragment growing 
approach aimed at exploring the P1 and P2 pockets (Hung et al. 2009). The introduction of a 
carboxylate group at either the C-2 or N-1 position halved the KD value (0.5 mM) while maintaining a 
high LE (~ 0.30). The carboxylic acid group at C-2 was replaced by an acyl sulfonamide, a flexible 
moiety that maintains the acidity of the carboxylic acid and allows the compound to bend in either P1 or 
P2 pockets. Among different acyl sulfonamides, 3 carrying a methylpyridine group able to occupy P2, 
was found by ITC to give a KD of 29 µM (LE = 0.26). The introduction of the acetate on N1 (4) gave an 
increase in the affinity (KD) to 1.5 µM.  
 Benzofuran-2-carboxylic acid 1 was found to bind in P1 simultaneously with 2, 3.1 Å away from 
the binding site of the methoxyindole. Structural data was used to guide the development of an 
acylsulfonamide linker to merge the two fragments into a single lead molecule, 7 (KD = 1.8 µM, LE = 
0.26). The X-ray crystal structure of compound 7 revealed that the linked compound maintains the 
binding modes of the original fragments. In a further study compounds 3 and 7 were explored from a 
group efficiency (GE) analysis which in an effort to improving their binding affinities, (Hung et al. 2016). 
GE analysis showed that the components that had the highest positive impact to the binding were the 
indole group (GE = 0.75) and the alkyl carboxylate substituent on N1 (GE between 0.35 and 0.43). The 
synthesis of several acyl sulphonamides analogues led to a series of inhibitors, the best compound 5 
having a KD of 0.20 µM (LE = 0.30) and an IC50 of 5.7 µM.  Based on the X-ray crystallographic data, a 
methylene linker was introduced between the sulfonamide and the phenyl group in order to push the 
trifluoromethyl group deeper into the pantoate binding site, giving compound 6 with an IC50 value of 250 
nM.  
 
 
Fig. 2. Fragment growing and merging strategies leading to the development of inhibitors of 
pantothenate synthetase (PS) (PDB codes: 3IMG, 4MUK) 	
 
(b) Cytochrome P450 (CYP121) 
The cytochrome P450 enzymes (CYPs) are potential targets for the treatment of Mtb infections. The 
discovery of the unusually large number of CYPs encoded in the mycobacterium genome (20 in the 
4.4Mb Mtb H37Rv genome vs 57 in the 3Gb human genome) underlines the importance of this class of 
enzymes, mainly in relation to the virulence and the survival of the mycobacterium (Cole et al. 1998) 
(Hudson, McLean et al. 2012). This family of mono-oxygenase enzymes catalyzes the oxidation of 
organic substrates due to the presence of a heme cofactor. The unique cytosolic localization of bacterial 
CYPs as well as their use of a different electron donor system, more specifically a two-component 
system comprising a FAD-containing ferredoxin reductase and an iron-sulfur cluster containing 
ferredoxin, represent good starting points for the development of selective inhibitors.    
 The structures and specific functions of only five Mtb CYPs have been disclosed so far, 
CYP51B1 is involved in the biosynthesis of sterols while CYP124, CYP125 and CYP142 constitute a 
pathway for the metabolism of host-derived steroids. CYP121 is the most promising TB drug target 
among the different CYPs; it is exclusive to Mtb and mediates the formation of mycocyclosin catalysing 
the formation of a C-C bond between the two tyrosine residues of the substrate cyclodityrosine (cYY), 
the product of the cyclodipeptide synthetase Rv2275 that is associated in an operon-like structure with 
Rv2276, the gene encoding for CYP121 (Belin, et al. 2009). This unusual reaction catalysed by CYP121 
takes place in a unique binding site, thus improving the chance of achieving selectivity over other CYPs. 
Further evidence for CYP121 essentiality has been shown that it was impossible to obtain a CYP121 
knock out mutant unless a complementary vector is present (McLean et al. 2008). The apo X-ray crystal 
structure of CYP121 was solved to high resolution revealing a highly-constrained active site and 
allowing the protein to be considered a strong candidate as potential target from a FBDD point of view 
(Leys et al. 2003). While a number of azole antifungals are known to inhibit CYP121 via a type II azole-
heme coordination, they possess limited selectivity over other mammalian CYPs.  
 Hudson and co-workers explored a fragment-based approach to targeting CYP121 (Hudson, 
McLean, Surade et al. 2012) (Fig. 3). A fragment screen was conducted using an fluorescence based 
thermal shift analysis as a first-line screen on a library of 665 ‘rule of three’ compliant fragments, which 
identified 66 hits causing an increase of the melting temperature of CYP121 by +0.8 °C or greater at a 
concentration of 5 mM (hit rate of 9.9%), 46% of these hits were confirmed using NMR  (STD and 
WaterLOGSY) which also showed cYY displacement, suggesting a potential binding mode into the 
active site of the protein. These fragments were soaked into CYP121 crystals and four X-ray crystal 
structures were obtained, all with the fragments located in the CYP121 active site. Two main distinct 
binding modes were observed: fragments 8 and 9 were characterized by a type II heme binding mode 
via the arylamine nitrogen and π-π interactions with the prosthetic group, while fragment 10 
(characterized by the ability to bind in two different conformations) adopted an unusual binding mode 
with the azole moiety not involved in the coordination of the iron. The binding affinity of the fragments 
was determined by ITC, with the best hit being 9 (KD = 400 µM, LE = 0.39). Fragment merging 
strategies were applied to the two overlapping heterocycles and resulted in a small library of 
aminoquinolines with improved affinity compared to the initial hits, the best derivative was 1,2,4-
triazolylquinoline 11 with a KD of 28 µM (LE = 0.39). The analysis of the analogues of 11 showed that 
the aniline group was the main contributor to the binding (GE = 2.6 Kcal mol-1). The crystal structure of 
11 in complex with CYP121 proved that the compound retains the binding mode of the parent 
fragments, with the arylamine involved in heme coordination and the five membered ring interacting via 
a water mediated H bond with a heme carboxylate. 
Additional merging strategies with the fragments binding further from the heme did not improve the 
binding affinities. In particular compound 12, derived from two different configurations of fragment 10, 
proved to be less active than the original fragment hit (KD = 2.8 mM), with quantum mechanical 
calculations suggesting this result was due to a steric clash of the ortho-hydrogen atoms of the opposite 
phenol groups (Hudson et al, 2013). The replacement of the original five-membered 1,2,4-triazole ring 
with an aminopyrazole led to 13, with a KD of 40 µM which was a 70 fold more potent than the original 
fragment 12. The growth into the large CYP121 water-filled active site finally yielded 14, whose 
additional phenol ring protrudes into the active site creating H-bonds with the interstitial solvent. The 
compound was the first high affinity ligand for CYP121 (KD= 15 µM, LE = 0.23) whose binding was not 
due to heme coordination. This compound was the subject of further medicinal chemistry efforts aimed 
at improving the potency and addressing the low ligand efficiency of the compound (Kavanagh et al, 
2016). A deconstruction approach, pursued by the synthesis of retro-fragments of the derivative, defined 
the GE for the tree aromatics ring, from which it emerged that the aromatic ring linked to the nitrogen 
was responsible for a small contribution (GE between -0.03 and 0.08), therefore it was removed. 
Examination of the binding mode showed a possible vector of growth from the meta position of the 
aromatic ring closer to the aniline group towards the heme cofactor, as a way to incorporate a metal 
binding group. The introduction of a 3-aminophenyl group gave 15, which exhibited excellent affinity for 
CYP121 with a KD= 0.015 µM (LE= 0.41) which to date is the highest affinity compound developed for 
CYP121. 
 
Fig 3. (a) Fragment merging strategies targeting CYP121 (PDB codes: 4G45, 4G44, 4G1X) (b) 
Fragment elaboration strategies targeting CYP121 (PDB codes:  4G47, 4KTL, 5IBE) 
 
 
(c) Protein tyrosine phosphatase 
The reversible phosphorylation of tyrosine in both prokaryotic and eukaryotic cells is at the heart of a 
large number of biological processes, where it acts as key regulator in the protein functionality of all 
living systems. This process is mediated by the opposite action of tyrosine phosphorylases and 
phosphatases (Tonks, 2006). In prokaryotic cells, protein tyrosine phosphatases (PTPs) are implicated 
in virulence and mediate the modification of host proteins in order to favour the spread of the 
microorganism. From the analysis of the Mtb genome, the presence of two PTPs, MPtpA and MPtptB, 
has been revealed (Cole et al. 1998). The lack of endogenous tyrosine phosphorylation in Mtb suggests 
that Mtb PTPs act as modulators of the macrophage proteins leading to attenuation of the host immune 
defences by interfering with the interferon-γ signalling pathway. Although not essential for extracellular 
survival of Mtb in vitro, the target has been validated by proving that genetic depletion of MPtpB impairs 
the ability of the pathogen to survive in the presence of interferon-γ activated macrophages in a guinea 
pig model, leading to a 70-fold lower bacillary load compared to the parental strain (Singh, Rao et al. 
2003).  Further, the peculiar localization outside the highly impermeable mycobacterium cell wall 
improves the appeal of Mtb PTPs as drug targets.  The issues arising from the highly conserved amino 
acidic sequence of the PTP active site within different species have been overcome with the discovery 
of unique secondary binding sites, that share less homology and permit the achievement of selectivity 
(Barr et al. 2009). There has been a number of efforts to target these enzymes and selective inhibitors 
have been obtained by using a Click chemistry approach to create bidentate ligands targeting the main 
active site and the secondary site at the same time, as well as from HTS of natural compound libraries. 
(Tan et al.  2009) (Schmidt et al. 2011)(Mascarello et al. 2013). 
 Ellman and co-workers employed a new substrate-based fragment approach termed "substrate 
activity screening" (SAS) to identify new MPtpB inhibitors. In this approach, the fragment hits were 
identified from a library of PTPs potential substrates (a set of 140 structurally diverse, low molecular 
weight O-aryl phosphates with different structural features) and subsequently underwent a fragment 
elaboration and optimization process. Finally the phosphate group of the optimized substrates was 
replaced by a phosphate isostere, thus converting an optimal substrate into a selective and potent 
inhibitor (Soellner et al. 2007) (Fig. 4a).  
 The initial screening yielded seven promising scaffolds acting as MPtpB substrates (KM 
between 267 and 24 µM) (Fig. 4a). Among the hits, the biphenyl derivative 16 with a KM of 86 µM was 
selected for further medicinal chemistry efforts because of the favourable drug-like properties of the 
biphenyl scaffold, which is recognised as a privileged structure. The introduction of a m-trifluoromethyl 
and p-fluoro substituents on the original scaffold allowed a 4-fold and 2-fold decrease in KM respectively, 
while merging both the substitution patterns provided 17 (KM= 13 µM). Compound 17 was converted 
from substrate to inhibitor via replacement of the phosphate group with the monoacidic isosteres, 
isothiazolidinone and isoxazole carboxylic acid. The latter furnished a promising inhibitor 18 with Ki of 
2.50 µM (Ki= 8.80 µM for the isothiazolidinone). In order to further improve the potency of the 
compound, modifications inspired by the structural similarity between the fragment hits previously 
identified were applied, generating isoxazole 19, which is currently the most potent inhibitor of MPtpB 
reported to date with a Ki of 0.22 µM and >200-fold selectivity over the MPtpA and different human 
PTPs. 
 Ellman and co-workers have also conducted a SAS screening on MPtpA by creating a small 
library of difluoromethylphosphonic acids (Rawls et al. 2009)(Fig. 4b). The most promising compound 
obtained from the preliminary SAR investigations was the benzanilide 20 (Kib= 24µM). Different 
substituents were then introduced on the phenyl ring mounted on the nitrogen of the amide functionality; 
introduction of electron withdrawing group, especially in the meta or para position gave excellent affinity. 
Compound 21 was the best derivative identified (Ki = 1.4 µM), with >70-fold selectivity over MPtpB thus 
allowing the compound to be considered a good molecular probe for the investigation of the different 
biological roles of the two enzymes. Further elaboration aimed at replacing the amide group yielded 22 
as the best derivative (Ki = 3.1µM), showing the difficulty of replacing the amide. 
 
Fig. 4. Substrate activity screening targeting (a) MPtpB and (b) MPtpA  
 
(d) 7,8-Diaminopelargonic acid (DAPA) synthase (BioA) 
The biotin biosynthetic pathway in Mtb has emerged as a potential drug target because of its essentiality 
for Mtb survival both in vitro and in vivo, whereas this pathway does not exist in human hosts. 7,8-
Diaminopelargonic acid (DAPA) synthase (BioA), which catalyses the second step of biotin biosynthesis 
from pimeloyl-CoA, was shown to be important for persistence in a murine model of TB.(Park et al, 
2011) Furthermore, biotin deprivation of the ΔbioA Mtb mutant led unusually to cell death, rather than 
growth arrest, indicating the possibility of targeting BioA as an anti-tubercular strategy. Previous efforts 
had identified the microbial natural product amiclenomycin (ACM) and its derivatives as inhibitors of Mtb 
BioA in bacterial cells, but these showed low efficacy in animal models, while other ACM analogues 
showed improved stability but lower potency.(Hotta et al, 1975)(Shi et al, 2012) 
 Finzel and co-workers were the first to apply FBDD to identify new inhibitors of BioA (Dai et al, 
2014). A library of ca. 1,000 fragments was screened at 5 mM using a thermal shift assay. Nine 
compounds exhibited positive Tm shifts larger than 2 °C, while 12 molecules showed negative shifts 
greater than 2 °C. In particular, 2-(aminomethyl)-benzothiazole 23 (Fig. 5) showed a negative shift of -
7.0 °C at 5 mM, and was subjected to crystallization with BioA. The results showed that compound 23 
bound to a pocket adjacent to the oxidized pyridoxamine (PLP) co-factor, forming hydrogen-bonding 
interactions with both PLP and several residues of the enzyme, mimicking interactions made by the 
natural substrate 7-keto-8-aminopelargonic acid (KAPA). The binding of 23 to BioA was further 
confirmed by ligand-based STD NMR experiments. 
 In the structure-guided fragment optimization campaign, 9 commercially available 
benzothiazoles related to 23 were evaluated using the thermal shift assay. Of these analogues, the 
hydrazine derivative 24 exhibited the largest negative thermal shift of -19 °C. Interestingly, addition of 24 
to either PLP-bound or apo-BioA led to the formation of a deep red color. The crystal structure of 24 with 
BioA showed the hydrazine group formed a covalent adduct with the PLP aldehyde to form a cis-azo 
quinonoid moiety. Additionally, and unlike compound 23, the molecule also induced significant and 
diverse conformational shifts in multiple regions of the enzyme, which was determined using X-ray 
crystallography. Kinetic experiments showed that 24 was a competitive reversible inhibitor of BioA with 
respect to the amino donor S-adenosyl methionine (SAM) (Ki = 10.4 ± 0.6 µM) and uncompetitive with 
respect to KAPA (Kiu = 85.4 ± 3.4 µM). The authors proposed that by forming a reversible covalent 
adduct between 24 and the PLP cofactor, subsequent reaction of PLP-BioA with SAM is prevented. 
Interestingly, while isoniazid also bound covalently to PLP in a co-crystal structure with BioA, it showed 
no inhibition in the BioA activity assay, suggesting that the isoniazid-PLP adducts observed 
crystallographically are very easily dissociated upon exposure to the natural substrates.   
 The unexpected conformational shifts of BioA induced by these molecules could potentially 
provide fertile grounds for the development of inhibitors that stabilize catalytically-inactive forms of the 
enzyme. This study also highlights that destabilizing fragment hits, i.e. those that induce a negative 
thermal shift, can also provide worthwhile scaffolds for investigation, which stands in contrast to most 
fragment screening campaigns where only molecules inducing positive thermal shifts are considered. 
 
(e) Protein antigen 85C 
An interesting approach was employed by Schade and co-workers in their development of inhibitors 
targeting Mtb antigen 85C (Ag85C).(Scheich et al, 2010) Mycolyl transferases antigens (Ag) 85A, 85B 
and 85C catalyze the transfer of mycolates between trehalose monomycolate (TMM) and trehalose 
mycolate (TDM), which are important components of the mycolyl-arabinogalactan-peptidoglycan 
(mAGP) complex of the mycobacterial cell wall.(Belisle et al, 1997) Genetic knockout of Ag85A 
abolished Mtb replication in human and mouse macrophages, while knockout of the Ag85C gene 
significantly lowered the amount of mycolic acids linked to the cell wall.(Jackson et al, 1999) Thus, 
inhibition of the Ag85A-C enzymes represents a potential strategy to inhibit the growth of Mtb. 
 Wary of the poorly drug-permeable nature of the mycobacterial cell wall, the top six hits 
identified by protein-observed 15N-HSQC NMR spectroscopy from a library of 5,000 synthetic fragments 
were immediately subjected to whole-cell assays before further optimization of the compounds. Only 
one of six compounds, 25 (Fig. 5), showed growth inhibitory activity against M. smegmatis, a model 
strain that shares Ag85A and Ag85C with Mtb, but not against E. coli and B. subtilis, which lack the 
Ag85 gene family. While an X-ray co-crystal structure could not be obtained, 15N-HSQC NMR analysis 
indicated that 25 binds to the active site or directly adjacent site of Ag85C. Derivatization of 25 afforded 
molecules 26 and 27 as the top analogues that inhibited the growth of both Mtb H37 and multi-drug 
resistant Mtb. Comparison of the structures of 26 and 27 with known substrates and inhibitors 
suggested that the alkyl chain of the molecules binds to the mycolyl channel of Ag85C, while the 
heterocyclic moiety binds to the trehalose recognition site. Notably, this study was the first to establish 
Ag85C as a therapeutic target for multi-drug resistant Mtb. Additionally, this study highlights the 
possibility that whole-cell assays can be used very early on in the fragment optimization process.  
 
Fig. 5. (a) Fragment optimization of a BioA inhibitor. (b) Fragment-based discovery of Ag85C inhibitors. 
 
(f) EthR 
Ethionamide is a second-line drug used for treating multidrug-resistant Mtb. Mechanistically, it functions 
as a prodrug that is activated by EthA, a flavin-containing monooxygenase enzyme in Mtb EthA.(Vanelli 
et al, 2002) EthA catalyzes the formation of an ethionamide-NAD adduct that inhibits the 2-trans-enoyl 
reductase enzyme InhA, thereby leading to the impairment of the type II fatty acid synthase system 
(FAS II) in Mtb. However, the efficacy of ethionamide is reduced by the activity of EthR, a TetR-type 
transcriptional repressor that reduces the expression of EthA. (Engohang-Ndong et al, 2004)  Therefore, 
the inhibition of EthR would be expected to enhance the expression of EthA, thus potentiating the 
efficacy of ethionamide and allowing for reduced dosages of the drug to be used. 
 EthR exists as a homodimer in solution, and each monomer is comprised of nine α-helices. 
The first three α-helices of each monomer comprise the DNA-binding “head”, and the two heads of the 
dimer must be in close proximity in order for EthR to bind to DNA. However, in the crystal structures of 
EthR with adventitious hexyl octanoate or 1,4-dioxane molecules, the DNA-binding heads are shifted 
apart by some 18 Å, resulting in a conformation that is incompatiable for binding to DNA.(Frenóis et al, 
2004)(Dover et al, 2004) Previous studies by the groups of Baulard and Deprez found that molecules 
capable of inhibiting the DNA-binding of EthR could boost ethionamide activation both in vitro and in 
vivo, validating EthR as a potential Mtb target.(Willand et al, 2009)(Flipo, 2011)(Flipo, Desroses, Lecat-
Guillet, Dirié et al, 2012)(Flipo, Desroses, Lecat-Guillet, Villemange et al 2012) 
 In 2014, the groups of Willand and Deprez applied different fragment-based methods to 
discover novel inhibitors of EthR. (Villemange et al, 2014) The starting fragment 28 (Fig. 6) was 
observed in an X-ray co-crystal structure to bind twice to each EthR monomer; once in the D1 “known 
binding pocket”, and once in the region defined by the subpockets D2 and D2ʹ. Fragment 28 showed 
very weak stabilization of EthR in a thermal shift assay (ΔTm = +0.1 °C), but was inactive against Mtb 
growth in macrophages (EC50 > 10 µM). Adopting a fragment growing approach, a virtual library of 976 
derivatives of 28 was designed and docked against the crystal structure of EthR in silico in order to 
identify analogues that could grow out of the relatively thin and linear D1 pocket. Ten high-scoring 
molecules from the virtual screening campaign were synthesized and tested in vitro, from which the 2-
methylthiazol-4-yl derivative 29 (ΔTm = +6.1 °C, EC50 = 5.7 µM), emerged as the top candidate. Four 
analogues of 29 bearing various modifications to the isopentyl tail of the sulfonamide group were 
designed and synthesized. The trifluoropropyl-substituted compound 30 (ΔTm = +8.5 °C, EC50 = 0.29 
µM) showed 20-fold higher in vitro potency than lead 29, and was also more effective against EthR 
DNA-binding as measured using an SPR assay (IC50 = 0.55 µM versus 4.9 µM for 29). Replacing the 
sulfonamide linker with an amide moiety generated compound 31, the most potent compound of this 
series (ΔTm = +11.2 °C, EC50 = 0.08 µM, IC50 = 0.4 µM). An X-ray crystal structure of 31 with EthR 
showed that the molecule was successfully grown out of the D1 pocket into the D2 pocket, and 
additionally, revealed that 31 not only recapitulated the important H-bonding interaction with Asn179 as 
observed for the original fragment 28, but also formed a new H-bond with Asn176, which could account 
for its improved activity over lead structures 29 and 30 which lack this second interaction. 
 Two molecules of the starting fragment 28 could be accommodated within the binding channel 
of an EthR monomer. Fragment merging and fragment linking approaches were also attempted using 
the optimized compound 31 and a second molecule of fragment 28, this generated the merged 
compound 32 and the linked compound 33, respectively. However, these two molecules showed 
reduced potency compared to compound 31, possibly due to lowered solubility as the number of heavy 
atoms increased, as well as limitations in the choice of connecting groups when linking or merging the 
two scaffolds together while maintaining the desired interactions. Thus, the authors concluded that the 
fragment growing strategy was more suitable for exploring the chemical space of the relatively rigid and 
lipophilic EthR ligand binding pocket.  
 
 
Fig. 6. Fragment strategies to develop inhibitors of EthR. (a) Fragment growing (b) Fragment merging 
and fragment linking.  
 
 In 2014 a fragment-based strategy to target EthR was reported by Surade and co-workers. 
(Surade et al, 2014) A library of 1250 fragments were screened against EthR using a thermal shift 
assay, and 86 fragments were identified which gave ΔTm values greater than +1.0 °C. These were 
subsequently tested in an SPR assay to measure their ability to inhibit the EthR-DNA interaction. Of 
these 86 fragments, 45 fragments inhibited the EthR-DNA interaction by more than 10% at 500 µM, 
giving a final hit rate of 3.6%. A number of fragments were successfully crystallized with EthR. Of 
interest was an amide 34 (IC50 = 280 µM), which bound twice to a single EthR monomer, together with 
two molecules of 1,4-dioxane. Interestingly, the binding of this compound appeared to induce significant 
conformational changes in the structure of the protein, particularly movements in the side chains of 
Phe184 and Glu125, which allowed the second molecule to occupy a previously unexploited cavity in 
EthR. As two molecules effectively spanned the entire binding channel, a fragment linking strategy was 
pursued. Dimeric molecules with different linker regions were docked against EthR in silico using GOLD, 
and the results showed that disulfide and amide linkers offered suitable geometry for the fragments to 
retain their original binding conformation. Five linked molecules were synthesized, and the most potent 
compound against EthR DNA-binding activity (IC50 = 0.97 µM) was linked using a disulfide group. 
Among the dimeric molecules, the disulfide-linked compounds showed significantly higher potency than 
the amide-linked compounds, which was attributed to the rigidity of the amide bond preventing individual 
arms of the molecule from forming favorable hydrophobic or hydrogen bond interactions with the binding 
site. A crystal structure of the linked compounds with EthR showed that the molecule maintained the 
same overall binding mode as with the starting fragment, including the key hydrogen bonding interaction 
with Asn179.  
 Following on from this work, Abell and co-workers have employed a fragment merging strategy 
to generate improved inhibitors of EthR.(Nikiforov et al 2016) In X-ray crystal structures, fragments 34 
and 35 each bound twice to the EthR monomer, and together the two fragments spanned the entire 
length of the EthR binding cavity. Merging of fragments 34 and 35 yielded lead structure 36 (IC50 = 35 
µM), which showed an 8-fold improvement in the inhibition of EthR DNA-binding activity compared to 
fragment 34 (IC50 = 280 µM). X-ray crystal analysis revealed that 36 recapitulated the binding poses of 
the two initial fragments, including the key hydrogen bonding interaction with Asn179, justifying the use 
of the fragment merging strategy. Structural exploration around the lead compound 36 by SAR 
generated nitrile 37, which showed a five-fold increase in binding affinity as measured by ITC (KD = 1 
µM) and a 10-fold improvement in EthR DNA-binding inhibition (IC50 = 3 µM). Interestingly, replacement 
of the amide group of 37 with a urea functionality and/or substitution of the nitrile group with an ester 
gave molecules with comparable potency, suggesting that these compounds could represent a 
privileged scaffold for EthR binding. An attempt to merge together one molecule of 34 and two 
molecules of 35 was comparatively less successful, as the molecules generated, although exhibiting 
high thermal shift values (+8.3–9.2 °C against EthR) showed reduced ability to perturb the EthR-DNA 
interaction compared to 36. However, none of the merged molecules in this study were able to boost 
ethionamide activity in infected macrophages, which the authors attributed to their inability to penetrate 
the mycobacterial envelope and/or the host cell membrane. 
 
Fig. 7: Fragment merging strategies to develop inhibitors of EthR.  
 
 While the literature contains successful examples of inhibitors developed from fragment-based 
approaches there still remains a number of shortcomings to this technique. Phenotypic or high-
throughput screening (HTS) identifies compounds that are cell permeable early on in the drug discovery 
process. However, fragment-based approaches use the isolated enzyme of interest and consequently 
the elaborated compounds are not screened for cell permeability until much later. Optimizing cell 
permeability at the later stages of development can prove challenging. One key aspect of the fragment-
based approach is that the target protein needs to be isolated in a stable form and in sufficient quantities 
for screening.  The target also needs to be crystallisable for X-ray protein crystallography in order to 
determine the binding mode of the fragments. These factors affect what targets can be screened. 
Without a stable, high yielding expression of the target the fragment-based approach is difficult.  
 Fragment libraries are normally composed of flat heterocycles and these tend to lead to 
compounds with these heterocycles at their core. Antibacterial drugs which are typically derived from 
natural products, can have multiple chiral centres and oxygen-containing functional groups. Such 
scaffolds are under represented in fragment libraries, and it could be difficult to develop compounds 
using this approach against these targets using the fragment based approach. There have been efforts 
to include more ‘3D like’ fragments in screening libraries, however the success of these has been 
somewhat limited.  
 Within our own laboratory we have had a number of success with a range of targets using 
fragment-based approaches ranging from protein-protein, protein-ligand and protein-DNA interactions. 
However, in some cases this approach has proved unsuccessful and in the case of shikimate kinase, an 
anti-tubercular target, we were unable to get any validated fragment hits (K. Bromfield, D. Osborne, S. 
Surade, T.L. Blundell, C. Abell, unpublished results). We have also had a long standing interest in the 
cytochrome P450’s from M. tuberculosis, and while CYP121 (see above) was successfully targeted 
using this approach, other cytochrome P450’s such as CYP144 have proved much more difficult to 
identify fragment hits (M.E. Kavanagh, C. Abell unpublished results). Each target needs to be taken on 
its own individual merits and it is not a case that what works for one target will necessarily work for 
another. However on the flip side fragment-based approaches have been shown to be successful with 
challenging targets such as GPCR’s and protein-protein interactions where traditional HTS has failed.  
 
CONCLUSION: 
Fragment based approaches to drug discovery are been utilised on several TB drug discovery projects 
in both academia and industry. This has enabled the development of potent inhibitors of a range of 
targets. With the emergence of drug resistant strains of Mtb this new approach to the design of possible 
therapeutics is a welcome addition to our armoury.  
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